Only a small number of oral vaccines are available for routine immunisations despite a significant research effort and a number of obvious advantages over parenteral vaccination.
Background
Oral delivery of agents such as vaccines offers a number of significant advantages over parenteral routes. Among the practical advantages are the lack of a requirement for needles and syringes and the reduction in the need for trained personnel for vaccine administration, enabling reduced costs and improved potential sustainability of global immunisation programs as required in the current WHO global immunisation strategy. 1 For example, the oral polio vaccine program is one-tenth the cost of the injectable polio program 2 and compared to the previous injectable vaccine, the oral cholera vaccines are more efficacious (although still suboptimal), cost effective and safer. 3 Despite such advantages, only a small number of oral vaccines are routinely available for use today with the results of many oral vaccine trials being variable and suboptimal at best. Lack of success is most commonly attributable to a lack of ability to target a vaccine to the mucosal immune system in the gastrointestinal tract. Non-targeted systems demonstrate low uptake of antigen in both tissue culture and animal tissue, 4 therefore antigen needs to be targeted to cells that have the ability to specifically take it up, present it in an appropriate form to the mucosal immune network and consequently stimulate a consistent response to protect from infectious challenge.
Most approaches have relied on the delivery of large amounts of antigen to the small intestine in the hope that there will be sufficient random uptake to induce an effective immune response. M cells, which overlay the lymphoid aggregates in the small intestine, determine how the host will subsequently respond to particulate antigenic material in the small intestine. However, specific receptor requirements for M cell uptake and transcytosis of bacterial antigen has been a challenge due to the lack of differentiation of M cell receptors from those that are also present on their neighbouring enterocytes. We 5 and others 4, 6, 7 have now identified and confirmed that it is a combination of receptor type and relative location that triggers the translocation events that precede mucosal response to particulate antigen in the gastrointestinal tract. One of the major remaining challenges is developing an understanding of the signalling mechanisms that initiate antigen uptake and how to specifically target the antigen to these cells.
Direct targeting of M cells will result in: optimisation of a number of oral bacterial, viral and synthetic vaccine delivery technologies currently available, leading to rapid application to clinical oral immunisation studies; oral immunisation schedules that provide more consistent and predictable immune responses; the inclusion of a broader range of antigens in oral vaccine formulations than is currently possible; and potential immune modification strategies for autoimmune diseases and inflammatory conditions of the bowel.
The intestinal epithelium is one of the major interfaces between the external and internal environments. It undertakes the essential processes associated with digestion and absorption of nutrients and functions as a barrier that responds to harmful agents, eg. infectious pathogens. Hence, the intestinal epithelium is a complex system of specialised cells including columnar absorptive Evidence would suggest that this type of sampling is the prime physiological role for M cells and that they transcytose and present particulate systems more effectively than their neighbouring enterocytes. 9 Three challenges have been identified in the specific targeting and subsequent transcytosis of antigen by M cells:
(1) The availability of appropriate experimental models to study M cell targeting and transcytosis;
(2) The development of appropriate tools for investigating the specificity of targeting; and (3) The identification of priority targets on the apical surface of M cells.
Challenge 1: appropriate experimental models
Research associated with the way M cells in the intestine sample antigens has been hampered due to the lack of appropriate in vivo and in vitro experimental models. The relatively low numbers of M cells in the gastrointestinal tract (GIT) and the inter-species variability in surface receptors have made in vivo systems difficult to establish. 4 An in vitro model using a human colonic adenocarcinoma cell line (Caco-2 cells) and mouse Peyer's patches was first described in 1997. 10 This has subsequently been demonstrated to be inadequate due to a lack of ability of researchers to reproduce the model and to quantify data obtained from the model. Our research developed modifications to this model that resulted in an experimental system which has been biochemically and physiologically verified, is reliable, reproducible and capable of quantification of experimental results. 11 One of the main difficulties is that M cells comprise only a small portion of an enterocyte population and similarly in vitro occur as about 30% of the population only when Caco-2 cells (enterocyte-like cells) are co-cultured with lymphoid cell suspensions. Hence, the major challenge to the validation of any cell culture model was to be able to verify that within the enterocyte cocultured population, a proportion of cells had adopted M cell characteristics and function. The uniqueness of our work is that for the first time the presence of M cells within Caco-2 cell co-cultures has been verified both microscopically and by the presence of cell characteristics known to be specific to intestinal M cells 11 and that we have confirmed the functional activity observed in vitro in an ex vivo animal model. 5 The other major model established to further investigate M cells was through the use of Caco-2 cells and a human lymphoblastoid B cell line (Raji B cells). 6 Both models have their strengths and weaknesses. The major weakness of our current model 11 is through the use of mouse Peyer's patches to stimulate conversion of the Caco-2 cells to M cells.
While this not ideal, all in vitro and in vivo experimental data with nontypeable Haemophilus influenzae (NTHi) demonstrated so far have correlated with human oral vaccine trials of Bronchostat®. 12 While some of the results of the Raji B model has been corroborated in human intestine, 13 the major weakness of the model is the lack of T cells that are now known to be required for optimal formation and function of M cells in vitro. Studying the specificity of antigen transcytosis has provided evidence that human M cells utilise receptor dependent transport mechanisms for both viral 16 and bacterial uptake. 11 We 5, 14 and others 13 have now clearly shown that via a receptor-mediated process there is differential uptake of bacteria for transcytosis by the M cells. By investigating the transcytosis of different bacteria, our results
showed that the respiratory pathogen nontypeable NTHi and Escherichia coli were poorly transcytosed by Caco-2 monocultures (measure of transfer due only to enterocytes) but were actively transcytosed in the M cell co-cultures (increase is associated with the activity of the M cells). 5 In contrast, there was no differentiation of transcytosis for Pseudomonas aeruginosa in the different cultures, being similarly endocytosed/transcytosed and to a more limited degree by both cell types (unpublished). P. aeruginosa can bind to toll-like receptor (TLR)-5 on polarised Caco-2 cells and villus enterocytes 17 whereas NTHi cannot 18 and this may explain the differences in transcytosis between the bacteria. These results were not an artefact of concentration because the bacterial uptake was saturable. platelet-activating factor receptor (PAFR) binds to the phosphorylcholine moiety of the surface lipooligosaccharide bacterial molecules; 22 and, α5β1 integrin binds, through endogenous fibronectin, to fibronectin-binding proteins expressed by many bacteria. 23 Adherence is the first step in the antigen-uptake process and it is believed to be mediated by PRRs and lectin-like microbial adhesins that can bind specific glycoprotein or glycolipid molecules on the apical surface of cells. 24 
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Our research using the in vitro M cell model and confirmation in ex vivo isolated murine intestinal segments demonstrate that M cells, but not Caco-2 cell monocultures, uptake and transcytose NTHi by specific receptor driven mechanisms. TLR-4, PAFR and α5β1 integrin are all involved in mediating uptake. 5 Not only does the pattern of expression of these receptors differ on M cells and enterocytes, our experiments demonstrated significantly reduced bacterial translocation using specific receptor inhibition studies. It is also feasible that M cell transcytosis is enhanced by synergy between different receptormediated signalling pathways. This hypothesis is supported by the reduction we have observed in the transcytosis of NTHi when TLR-4 and PAFR were blocked. 5 The bacterially expressed lipooligosaccharide (LOS) on NTHi mediates uptake in other cells through the PAFR. 22, 32 Plateletactivating factor (PAF), which is released by various cell types, may have a regulatory role in the GIT and this inflammatory mediator increases mucosal permeability of the intestine. 33 One mechanism by which PAF mediates movement of macromolecules across the mucosal barrier is via tyrosine phosphorylation of E-cadherin and cytoskeletal rearrangement of enterocytes. 33 The PAFR signals are transduced through the G-protein G qi by the calcium/inositol phosphate (Ca/IP 3 ) pathways and it is possible that bacterial LOS binding to the PAFR may activate these pathways.
However, the activation of the PAFR by bacterial LOS or LPS may not be straightforward with one study showing that LPS, but not PAF, activates the transcription factor nuclear factor (NF)-kappaB in the intestine via at least two mechanisms. 34 Our preliminary studies have shown that the GIT commensal Escherichia coli (LPS+) was preferentially transported by M cell co-cultures (compared with enterocytes) both in vitro and in mouse ex vivo studies and antagonists to PAFR and α5β1 integrin successfully blocked transport of both NTHi (LOS+) and E. coli through M cells in vitro and ex vivo. So, while the differences in the transcytotic processes that were observed between NTHi and P. aeruginosa are not necessarily specific for LOS and LPS, these could be used to identify differences in the M cell surface receptor signalling pathways compared to those of the adjacent enterocytes.
The role of the LOS sub-component phosphorylcholine (PC) also requires further study. Our observations that the blocking of PAFR with a specific receptor antagonist inhibits transcytosis of NTHi across M cells 5 and our recent preliminary data with a PC mutant NTHi strain which demonstrates that transcytosis of NTHi across M cells is at least in part PC dependent (unpublished)
is highly suggestive of a role for PC in M cell targeting.
Summary
A lack of delivery systems that target the gut M cells is a major roadblock in the development of oral vaccines. Fundamental knowledge and understanding of how intestinal M cells sample the intestinal milieu so that it is possible to target particulate matter for controlled and effective uptake in the gastrointestinal system is essential to create feasible options for sustainable, effective and cost efficient oral vaccination programs and immune modulation therapies for inflammatory triggers in the gut.
The emergence of ex vivo models that provide reproducible and quantifiable data and future knowledge of the essential PAMP-PRR interactions on M cells will provide the information that will enable the design of approaches for validation of the results in humans both in situ and in vivo.
The results will help distinguish the unique interactions and signal transduction pathways triggered in M cells compared with those triggered in their neighbouring enterocytes. This, in turn, will give insight into the cellular mechanisms in the gastrointestinal tract that allow antigen sampling and priming of the immune system resulting in prevention of disease. It will also assist in identifying products that prevent mucosally triggered inflammatory responses as well as food allergy conditions.
In the latter context we have recently published our work examining the effect of heat denaturation of bovine β-lactoglobulin on uptake. 35 Technology derived from the knowledge obtained from these studies will contribute to a large number of health care opportunities for novel therapeutics and oral vaccine technologies. Schematic representation of the structure of the Peyer's patch dome showing M cells within the enterocytes on the intestinal luminal surface and a representation of the apically expressed pattern recognition receptors (PRRs) that recognise microbial pathogen-associated molecular patterns (PAMPs). Some of the downstream signalling pathways known to be associated with activation of these PRRs have been shown.
